Idogen’s Board of Directors proposes that liquidation is not to be resolved at the Annual General Meeting on June 8.
Idogen has been contacted by serval stakeholders regarding an acquisition of the company’s proprietary technology platform for the manufacture of cell therapy aimed at creating tolerance. Discussions are ongoing in parallel, as previously announced, regarding a reverse merger acquisition. The board of Directors has therefore decided to propose that liquidation is not to be resolved at the Annual General Meeting on 8 June 2023, but that it is instead resolved to continue operation. This gives the Board additional time to find solutions that can be more beneficial to shareholders.